{"id":4331,"date":"2022-08-16T04:35:56","date_gmt":"2022-08-16T04:35:56","guid":{"rendered":"https:\/\/aceoncology.org\/?p=4331"},"modified":"2022-08-16T04:35:57","modified_gmt":"2022-08-16T04:35:57","slug":"fda-new-cancer-indications-approvals-june-july-2022","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/","title":{"rendered":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5"},"content":{"rendered":"\n<p>2022\u5e746\u67081\u65e5\u81f37\u670831\u65e5\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u8fbe\u62c9\u975e\u5c3c\u8054\u5408\u66f2\u7f8e\u66ff\u5c3c\u6cbb\u7597BRAF V600E\u7a81\u53d8\u7684\u80bf\u7624\u3002<\/strong>\u8fbe\u62c9\u975e\u5c3c\u8054\u5408\u66f2\u7f8e\u66ff\u5c3c\uff08\u6cf0\u83f2\u4e50\u00ae\u548c\u8fc8\u5409\u5b81\u00ae\uff0c\u8bfa\u534e\uff09\u88ab<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid\">\u52a0\u901f\u6279\u51c6<\/a>\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u6cbb\u7597\u540e\u8fdb\u5c55\u4e14\u65e0\u9002\u5408\u66ff\u4ee3\u6cbb\u7597\u9009\u62e9\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027BRAF V600E\u7a81\u53d8\u5b9e\u4f53\u7624\uff08\u7ed3\u76f4\u80a0\u764c\u9664\u5916\uff09\u6210\u4eba\u548c\u22656\u5c81\u513f\u7ae5\u60a3\u8005\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8e\u5f00\u653e\u6027\u3001\u591a\u961f\u5217\u7814\u7a76BRF117019\u548cNCI-MATCH\u5b50\u65b9\u6848H\u4e2d\u7eb3\u5165\u7684131\u4f8bBRAF V600E\u7a81\u53d8\u9633\u6027\u80bf\u7624\u6210\u4eba\u60a3\u8005\uff0c\u4ee5\u53caCTMT212X2101\u7814\u7a76C\u90e8\u5206\u548cD\u90e8\u5206\u768436\u4f8b\u513f\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u7597\u6548\u6570\u636e\u3002\u8be5\u6279\u51c6\u5f97\u5230\u4e86COMBI-d\u3001COMBI-v\u548cBRF113928\uff08\u4e4b\u524d\u5728\u4ea7\u54c1\u6807\u7b7e\u4e2d\u63cf\u8ff0\u7684\u9ed1\u8272\u7d20\u7624\u548c\u80ba\u764c\u7814\u7a76\uff09\u7ed3\u679c\u7684\u652f\u6301\u3002\u8fd9\u4e9b\u7814\u7a76\u603b\u5171\u5165\u7ec4\u4e8624\u79cd\u80bf\u7624\u7c7b\u578b\u7684\u60a3\u8005\uff0c\u5305\u62ec\u9ad8\u7ea7\u522b\u548c\u4f4e\u7ea7\u522b\u80f6\u8d28\u7624\u7684\u4e0d\u540c\u4e9a\u578b\u3002\u8fd9\u4e9b\u7814\u7a76\u7684\u4e3b\u8981\u7597\u6548\u7ed3\u5c40\u6307\u6807\u662f\u4f7f\u7528\u6807\u51c6\u7684\u7f13\u89e3\u8bc4\u4ef7\u4f53\u7cfb\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u3002\u5728131\u4f8b\u6210\u4eba\u60a3\u8005\u4e2d\uff0c54\u4f8b\uff0841%\uff09\u8868\u73b0\u4e3a\u5ba2\u89c2\u7f13\u89e3\u3002\u5728\u4ee3\u8868\u6027\u6700\u9ad8\u7684\u80bf\u7624\u7c7b\u578b\u4e2d\uff0c\u80c6\u9053\u764cORR\u4e3a46%\uff0c\u9ad8\u7ea7\u522b\u80f6\u8d28\u7624\u7684ORR\u4e3a33%\uff0c\u4f4e\u7ea7\u522b\u80f6\u8d28\u7624\u7684ORR\u4e3a50%\u300236\u4f8b\u513f\u7ae5\u60a3\u8005\u7684ORR\u4e3a25%\uff1b78%\u60a3\u8005\u7684\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\u22656\u4e2a\u6708\uff0c44%\u60a3\u8005\u7684\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\u226524\u4e2a\u6708\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Liso-Cel<\/strong><strong>\u6cbb\u7597\u4e8c\u7ebf\u5927<\/strong><strong>B<\/strong><strong>\u7ec6\u80de\u6dcb\u5df4\u7624\u3002<\/strong>\u4e00\u79cd\u81ea\u4f53\u3001\u9776\u5411CD-19\u3001\u5d4c\u5408\u6297\u539f\u53d7\u4f53\uff08CAR\uff09T\u7ec6\u80de\u7597\u6cd5\uff08liso-cel\uff1bBreyanzi\u00ae\uff0c\u5de8\u8bfa\u533b\u7597\uff09\u83b7\u5f97<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-second-line-treatment-large-b-cell-lymphoma\">\u6279\u51c6<\/a>\uff0c\u7528\u4e8e\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u96be\u6cbb\u6216\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u540e12\u4e2a\u6708\u5185\u590d\u53d1\u7684\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08LBCL\uff09\u6210\u4eba\u60a3\u8005\uff1b\u6216\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u96be\u6cbb\u75be\u75c5\u6216\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u540e\u590d\u53d1\uff0c\u4f46\u56e0\u5408\u5e76\u75c7\u6216\u5e74\u9f84\u800c\u4e0d\u9002\u5408\u63a5\u53d7\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\uff08HSCT\uff09\u7684\u60a3\u8005\u3002\u6279\u51c6\u662f\u57fa\u4e8e\u5728\u539f\u53d1\u6027\u96be\u6cbb\u6027LBCL\u6216\u4e00\u7ebf\u6cbb\u7597\u8fbe\u5230\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u540e12\u4e2a\u6708\u5185\u590d\u53d1\u7684\u60a3\u8005\u4e2d\u8fdb\u884c\u7684\u4e00\u9879\u968f\u673a\u3001\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc3\u7684<a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(22)00662-6\/fulltext\">TRANSFORM<\/a>\u7814\u7a76\u3002\u5171\u6709184\u4f8b\u60a3\u8005\u5728\u6dcb\u5df4\u7ec6\u80de\u6e05\u9664\u5316\u7597\u6216\u4e8c\u7ebf\u6807\u51c6\u6cbb\u7597\u540e\u63a5\u53d7\u4e86liso-cel\u5355\u6b21\u8f93\u6ce8\uff0c\u5305\u62ec3\u4e2a\u5468\u671f\u7684\u5316\u5b66\u514d\u75ab\u6cbb\u7597\uff0c\u968f\u540e\u5728\u8fbe\u5230CR\u6216\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\u7684\u60a3\u8005\u4e2d\u8fdb\u884c\u9ad8\u5242\u91cf\u6cbb\u7597\u548c\u81ea\u4f53HSCT\u3002\u4e3b\u8981\u7ed3\u5c40\u4e3a\u72ec\u7acb\u5ba1\u67e5\u59d4\u5458\u4f1a\uff08IRC\uff09\u8bc4\u4f30\u7684\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002\u4e2d\u4f4d\u968f\u8bbf6.2\u4e2a\u6708\uff0cliso-cel\u7ec4\u7684\u4e2d\u4f4dEFS\u4e3a10.1\u4e2a\u6708\uff0c\u6807\u51c6\u6cbb\u7597\u7ec4\u4e3a2.3\u4e2a\u6708\uff08\u98ce\u9669\u6bd4 [HR]\uff0c0.35\uff1bP &lt; 0.0001\uff09\u3002\u6279\u51c6\u5f97\u5230\u4e86\u5355\u81c2\u3001\u591a\u4e2d\u5fc3<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.16_suppl.7062\">PILOT<\/a>\u7814\u7a76\u7597\u6548\u7ed3\u679c\u7684\u652f\u6301\uff0c\u8be5\u7814\u7a76\u7eb3\u5165\u4e86\u4e0d\u9002\u5408\u79fb\u690d\u4e14\u80fd\u591f\u8010\u53d7\u4e8c\u7ebfCAR T\u7ec6\u80de\u6cbb\u7597\u7684\u60a3\u8005\u3002\u5728\u63a5\u53d7\u767d\u7ec6\u80de\u5206\u79bb\u672f\u768474\u4f8b\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u5e74\u9f84\u4e3a74\u5c81\uff0c61\u4f8b\uff0882%\uff09\u5b8c\u6210\u4e86liso-cel\u6cbb\u7597\u3002ORR\u4e3a80%\uff0cCR\u7387\u4e3a54%\uff0c\u7f13\u89e3\u6301\u4e45\u3002\u5904\u65b9\u4fe1\u606f\u5305\u62ec\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08CRS\uff09\u548c\u795e\u7ecf\u6bd2\u6027\u7684\u9ed1\u6846\u8b66\u544a\uff0c\u53ea\u80fd\u5728\u7ecf\u8fc7\u4e13\u95e8\u8ba4\u8bc1\u7684\u533b\u9662\u7ed9\u4e88\u6cbb\u7597\u3002Liso-cel\u4e0d\u9002\u7528\u4e8e\u539f\u53d1\u6027\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u6dcb\u5df4\u7624\u60a3\u8005\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u514b\u5511\u66ff\u5c3c\u6cbb\u7597<\/strong><strong>ALK<\/strong><strong>\u9633\u6027\u708e\u6027\u808c\u7ea4\u7ef4\u6bcd\u7ec6\u80de\u7624<\/strong>\u3002ALK\u6291\u5236\u5242\u514b\u5511\u66ff\u5c3c\uff08\u8d5b\u53ef\u745e\u00ae\uff0c\u8f89\u745e\uff09\u7684\u9002\u5e94\u75c7<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor\">\u6269\u5927<\/a>\u81f3\u5305\u62ec\u60a3\u6709\u4e0d\u53ef\u5207\u9664\u3001\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027ALK\u9633\u6027\u708e\u6027\u808c\u7ea4\u7ef4\u6bcd\u7ec6\u80de\u7624\uff08IMT\uff09\u76841\u5c81\u53ca\u4ee5\u4e0a\u6210\u4eba\u548c\u513f\u7ae5\u60a3\u8005\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8e2\u9879\u591a\u4e2d\u5fc3\u3001\u5355\u81c2\u3001\u5f00\u653e\u6027\u7814\u7a76\u7684ORR\u6570\u636e\u7ed3\u679c\uff0c\u5305\u62ec\u4e86ADVL091\u7814\u7a76\u768414\u4f8b\u513f\u7ae5\u60a3\u8005\u548cA8081013\u7814\u7a76\u76847\u4f8b\u4e0d\u53ef\u5207\u9664\u3001\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027ALK\u9633\u6027IMT\u6210\u4eba\u60a3\u8005\u3002\u572814\u4f8b\u513f\u7ae5\u60a3\u8005\u4e2d\uff0c12\u4f8b\u60a3\u8005\uff0886%\uff09\u8fbe\u5230\u5ba2\u89c2\u7f13\u89e3\uff08\u7531IRC\u8bc4\u4f30\uff09\uff0c\u57287\u4f8b\u6210\u4eba\u60a3\u8005\u4e2d\uff0c5\u4f8b\uff0871%\uff09\u8fbe\u5230\u5ba2\u89c2\u7f13\u89e3\u3002<\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>2022\u5e746\u67081\u65e5\u81f37\u670831\u65e5\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002 \u8fbe\u62c9\u975e\u5c3c\u8054\u5408\u66f2\u7f8e\u66ff\u5c3c\u6cbb\u7597BRAF V600 [&hellip;]<\/p>\n","protected":false},"author":691,"featured_media":4328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-4331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-42"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-16T04:35:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"526\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"j gao\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"j gao\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\"},\"author\":{\"name\":\"j gao\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf\"},\"headline\":\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\",\"datePublished\":\"2022-08-16T04:35:56+00:00\",\"dateModified\":\"2022-08-16T04:35:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\"},\"wordCount\":69,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg\",\"articleSection\":[\"\u65b0\u836f\u83b7\u6279\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\",\"name\":\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg\",\"datePublished\":\"2022-08-16T04:35:56+00:00\",\"dateModified\":\"2022-08-16T04:35:57+00:00\",\"description\":\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg\",\"width\":1000,\"height\":526},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf\",\"name\":\"j gao\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g\",\"caption\":\"j gao\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/jgao\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","description":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/","og_locale":"zh_CN","og_type":"article","og_title":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","og_description":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5","og_url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/","og_site_name":"ACE Oncology","article_published_time":"2022-08-16T04:35:56+00:00","article_modified_time":"2022-08-16T04:35:57+00:00","og_image":[{"width":1000,"height":526,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg","type":"image\/jpeg"}],"author":"j gao","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"j gao","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/"},"author":{"name":"j gao","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf"},"headline":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5","datePublished":"2022-08-16T04:35:56+00:00","dateModified":"2022-08-16T04:35:57+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/"},"wordCount":69,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg","articleSection":["\u65b0\u836f\u83b7\u6279"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/","url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/","name":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg","datePublished":"2022-08-16T04:35:56+00:00","dateModified":"2022-08-16T04:35:57+00:00","description":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/08\/Picture-Blog-Post-98_Drug-approvals-August.jpg","width":1000,"height":526},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-june-july-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"2022\u5e746\u6708-7\u6708FDA\u6279\u51c63\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf","name":"j gao","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g","caption":"j gao"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/jgao\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/691"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=4331"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4331\/revisions"}],"predecessor-version":[{"id":4332,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4331\/revisions\/4332"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/4328"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=4331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=4331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=4331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}